Skip to main content
SpringerLink
Log in

Biomarker des Knochenstoffwechsels in Serum und Urin bei ossären Metastasen

  • Chapter
  • First Online:
Knochenmetastasen

  • 1905 Accesses

Zusammenfassung

Ossäre Metastasen sind charakterisiert durch verstärkte osteolytische und/oder osteoblastische Prozesse. Es werden dabei, begünstigt durch eine erhöhte Stoffwechselaktivität und durch die destruktive Wirkung der Metastasierung, vermehrt Komponenten aus dem Knochenstoffwechsel in den Blutkreislauf abgegeben. Dies sind entweder an den Umbauprozessen direkt beteiligte Enzyme, dabei entstehende Metaboliten oder freigesetzte Knochenmatrixproteine. Diese Biomarker werden entsprechend ihrer Reflexion des Knochenaufbaus oder -abbaus in Knochenformations- und -resorptionsmarker eingeteilt. Im Kapitel werden die einzelnen Biomarker und ihre Bestimmungsmöglichkeiten beschrieben. Anhand von Literaturdaten wird der Einsatz von Knochenmarkern zu Fragestellungen der Diagnostik, Prognosebeurteilung und Therapieführung bei Patienten mit Skelettmetastasen von Mamma-, Prostata-, Lungen- und Nierenzellkarzinomen kritisch diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Alcaraz A, Gonzalez-Lopez R, Morote J et al (2013) Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer 109: 121–130

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ali SM, Demers LM, Leitzel K et al (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15: 455–459

    Article  CAS  PubMed  Google Scholar 

  • Ang C, Chambers AF, Tuck AB et al (2005) Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96: 803–805

    Article  CAS  PubMed  Google Scholar 

  • Aruga A, Koizumi M, Hotta R et al (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76: 760–764

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bauer D, Krege J, Lane N et al (2012) National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 23: 2425–2433

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bayrak SB, Ceylan E, Serter M et al (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17: 112–118

    Article  CAS  PubMed  Google Scholar 

  • Bombardieri E, Martinetti A, Miceli R et al (1997) Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24: 1349–1355

    Article  CAS  PubMed  Google Scholar 

  • Brasso K, Christensen IJ, Johansen JS et al (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66: 503–513

    Article  CAS  PubMed  Google Scholar 

  • Brown JE, Sim S (2010) Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 12: 685–696

    CAS  PubMed Central  PubMed  Google Scholar 

  • Brown JM, Vessella RL, Kostenuik PJ et al (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977–2983

    CAS  PubMed  Google Scholar 

  • Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69

    Article  CAS  PubMed  Google Scholar 

  • Chang YS, Kim HJ, Chang J et al (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57: 373–380

    Article  PubMed  Google Scholar 

  • Chao TY, Wu YY, Janckila AJ (2010) Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta 411: 1553–1564

    Article  CAS  PubMed  Google Scholar 

  • Chung JH, Park MS, Kim YS et al (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46: 388–393

    Article  PubMed Central  PubMed  Google Scholar 

  • Chung YC, Ku CH, Chao TY et al (2006) Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 15: 424–428

    Article  CAS  PubMed  Google Scholar 

  • Cloos PAC, Christgau S, Lyubimova N et al (2003) Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments. Breast Cancer Res 5: R103–R109

    Article  CAS  PubMed  Google Scholar 

  • Cloos PAC, Lyubimova N, Solberg H et al (2013) An immunoassay for measuring fragments of newly synthesized collagen Type I produced during metastatic invasion of bone. Clin Lab 50: 279–289

    Google Scholar 

  • Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935

    Article  CAS  PubMed  Google Scholar 

  • Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34: 629–639

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Coleman R, Costa L, Saad F et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 80: 411–432

    Article  PubMed  Google Scholar 

  • Cook RJ, Coleman R, Brown J et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12: 3361–3367

    Article  CAS  PubMed  Google Scholar 

  • de la Piedra C, Castro-Errecaborde NA, Traba ML et al (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45–53

    Article  Google Scholar 

  • de la Piedra C, Alcaraz A, Bellmunt J et al (2013) Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer 108: 2565–2572

    Article  Google Scholar 

  • Diel IJ, Solomayer EF, Seibel MJ et al (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919

    CAS  PubMed  Google Scholar 

  • Ebert W, Muley T, Herb KP et al (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193–3201

    CAS  PubMed  Google Scholar 

  • Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060–4066

    CAS  PubMed  Google Scholar 

  • Franjevic A, Pavicevic R, Bubanovic G (2011) ICTP in bone metastases of lung cancer. Coll Antropol 35: 43–47

    PubMed  Google Scholar 

  • Garnero P, Buchs N, Zekri J et al (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82: 858–864

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • He JJ, Zhi K, Liu GF (2011) Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer. Onkologie 34: 584–588

    Article  CAS  PubMed  Google Scholar 

  • Hegele A, Wahl HG, Varga Z et al (2007) Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 99: 330–334

    Article  CAS  PubMed  Google Scholar 

  • Heider U, Fleissner C, Zavrski I et al (2006) Bone markers in multiple myeloma. Eur J Cancer 42: 1544–1553

    Article  CAS  PubMed  Google Scholar 

  • Herrmann M, Seibel MJ (2008) The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 393: 57–75

    Article  CAS  PubMed  Google Scholar 

  • Jain A, McKnight DA, Fisher LW et al (2009) Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 15: 5199–5207

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Joerger M, Huober J (2012) Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 192: 197–223

    Article  CAS  PubMed  Google Scholar 

  • Jukkola A, Tahtela R, Tholix E et al (1997) Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57: 5517–5520

    CAS  PubMed  Google Scholar 

  • Jung K, Lein M, v. Hösslin K et al (2002) Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 17: 177–181

    CAS  PubMed  Google Scholar 

  • Jung K, Stephan C, Semjonow A et al (2003) Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170: 2302–2305

    Article  PubMed  Google Scholar 

  • Jung K, Lein M, Stephan C et al (2004) Comparison of ten serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783–791

    Article  CAS  PubMed  Google Scholar 

  • Jung K, Lein M, Ringsdorf M et al (2006) Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176: 1326–1331

    Article  PubMed  Google Scholar 

  • Jung K, Miller K, Wirth M et al (2011) Bone turnover markers as predictors of mortality risk of prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 59: 604–612

    Article  CAS  PubMed  Google Scholar 

  • Kamiya N, Suzuki H, Yano M et al (2010) Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 75: 1446–1451

    Article  PubMed  Google Scholar 

  • Kamiya N, Suzuki H, Endo T et al (2011) Significance of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol 16: 366–372

    Article  CAS  PubMed  Google Scholar 

  • Kanakis I, Nikolaou M, Pectasides D et al (2004) Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal 34: 827–832

    Article  CAS  PubMed  Google Scholar 

  • Kim JH, Skates SJ, Uede T et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671–1679

    Article  CAS  PubMed  Google Scholar 

  • Kiuchi K, Ishikawa T, Hamaguchi Y et al (2002) Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 9: 595–598

    CAS  PubMed  Google Scholar 

  • Klepzig M, Sauer-Eppel H, Jonas D et al (2008) Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Anticancer Res 28: 2443–2446

    CAS  PubMed  Google Scholar 

  • Koizumi M, Yonese J, Fukui I et al (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87: 348–351

    Article  CAS  PubMed  Google Scholar 

  • Koopmans N, de Jong IJ, Breeuwsma AJ et al (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178: 849–853

    Article  CAS  PubMed  Google Scholar 

  • Korpela J, Tiitinen SL, Hiekkanen H et al (2006) Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26: 3127–3132

    CAS  PubMed  Google Scholar 

  • Lara PN Jr, Stadler WM, Longmate J et al (2006) A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12: 1556–1563

    Article  CAS  PubMed  Google Scholar 

  • Lee AJ, Hodges S, Eastell R (2000) Measurement of osteocalcin. Ann Clin Biochem 37 (Pt 4): 432–446

    Article  PubMed  Google Scholar 

  • Leeming DJ, Delling G, Koizumi M et al (2006a) Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 15: 1392–1395

    Article  CAS  Google Scholar 

  • Leeming DJ, Koizumi M, Byrjalsen I et al (2006b) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15: 32–38

    Article  CAS  Google Scholar 

  • Lipton A, Chapman JA, Demers L et al (2011) Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol 29: 3605–3610

    Article  PubMed  Google Scholar 

  • Lumachi F, Santeufemia DA, Del Conte A et al (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33: 2593–2596

    CAS  PubMed  Google Scholar 

  • Marin L, Koivula MK, Jukkola-Vuorinen A et al (2011) Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 48: 447–451

    Article  CAS  PubMed  Google Scholar 

  • Meier C, Seibel MJ, Kraenzlin ME (2009) Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24: 386–388

    Article  PubMed  Google Scholar 

  • Michelsen J, Wallaschofski H, Friedrich N et al (2013) Reference intervals for serum concentrations of three bone turnover markers (PINP, BAP, CTX) in male and female adults. Endocr Rev 34: SAT–230

    Google Scholar 

  • Morovat A, Catchpole A, Meurisse A et al (2013) IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intrvals in adults in children. Clin Chem Lab Med 51: 2009–2018

    Article  CAS  PubMed  Google Scholar 

  • Mountzios G, Dimopoulos MA, Bamias A et al (2007) Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46: 221–229

    Article  CAS  PubMed  Google Scholar 

  • Mountzios G, Ramfidis V, Terpos E et al (2011) Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 12: 341–349

    Article  CAS  PubMed  Google Scholar 

  • Nanashima A, Takeshita H, Tobinaga S et al (2010) Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology 57: 694–697

    PubMed  Google Scholar 

  • Palma MA, Body JJ (2005) Usefulness of bone formation markers in breast cancer. Int J Biol Markers 20: 146–155

    CAS  PubMed  Google Scholar 

  • Pollmann D, Siepmann S, Geppert R et al (2007) The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27: 1853–1862

    CAS  PubMed  Google Scholar 

  • Rajpar S, Massard C, Laplanche A et al (2010) Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 21: 1864–1869

    Article  CAS  PubMed  Google Scholar 

  • Ramankulov A, Lein M, Kristiansen G et al (2007a) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67: 330–340

    Article  Google Scholar 

  • Ramankulov A, Lein M, Kristiansen G et al (2007b) Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133: 643–652

    Article  CAS  Google Scholar 

  • Rosenquist C, Fledelius C, Christgau S et al (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44: 2281–2289

    CAS  PubMed  Google Scholar 

  • Saad F, Eastham JA, Smith MR (2012) Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol 30: 369–378

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schafer AL, Vittinghoff E, Ramachandran R et al (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21: 439–445

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47: 1443–1450

    CAS  PubMed  Google Scholar 

  • Seibel MJ, Koeller M, Van der Velden B et al (2002) Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 48: 583–588

    CAS  PubMed  Google Scholar 

  • Shimozuma K, Sonoo H, Fukunaga M et al (1999) Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29: 16–22

    Article  CAS  PubMed  Google Scholar 

  • Som A, Tu SM, Liu J et al (2012) Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107: 1547–1553

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tamiya M, Kobayashi M, Morimura O et al (2013) Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer. Clin Lung Cancer 14: 50–54

    Article  CAS  PubMed  Google Scholar 

  • Tanko LB, Karsdal MA, Christiansen C et al (2006) Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? Cancer Metastasis Rev 25: 659–668

    Article  PubMed  Google Scholar 

  • Terpos E, Politou M, Rahemtulla A (2005) The role of markers of bone remodeling in multiple myeloma. Blood Rev 19: 125–142

    Article  PubMed  Google Scholar 

  • Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29: 1651–1657

    CAS  PubMed  Google Scholar 

  • Thurairaja R, Iles RK, Jefferson K et al (2006) Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76: 67–71

    Article  CAS  PubMed  Google Scholar 

  • Todenhofer T, Hennenlotter J, Leidenberger P et al (2013) Serum receptor activator of nuclear factor kappaB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy. BJU Int 113: 152–159

    Article  PubMed  Google Scholar 

  • Uccello M, Malaguarnera G, Vacante M et al (2011) Serum bone sialoprotein levels and bone metastases. J Cancer Res Ther 7: 115–119

    Article  CAS  PubMed  Google Scholar 

  • Ulrich U, Rhiem K, Schmolling J et al (2001) Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264: 186–190

    Article  CAS  PubMed  Google Scholar 

  • Vasikaran S, Cooper C, Eastell R et al (2011a) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49: 1271–1274

    Article  CAS  Google Scholar 

  • Vasikaran S, Eastell R, Bruyere O et al (2011b) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22: 391–420

    Article  CAS  Google Scholar 

  • Voorzanger-Rousselot N, Juillet F, Mareau E et al (2006) Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95: 506–514

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wada N, Fujisaki M, Ishii S et al (2001) Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8: 131–137

    Article  CAS  PubMed  Google Scholar 

  • Wakabayashi H, Nakajima K, Mizokami A et al (2013) Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med in press 27: 802–807

    Article  CAS  Google Scholar 

  • Woitge HW, Pecherstorfer M, Li Y et al (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792–801

    Article  CAS  PubMed  Google Scholar 

  • Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38: 284–291

    Article  PubMed  Google Scholar 

  • Yao NS, Wu YY, Janckila AJ et al (2011) Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta 412: 181–185

    Article  CAS  PubMed  Google Scholar 

  • Ylisirnio S, Hoyhtya M, Makitaro R et al (2001) Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7: 1633–1637

    CAS  PubMed  Google Scholar 

  • Zafeirakis AG, Papatheodorou GA, Limouris GS (2010) Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. Nucl Med Commun 31: 249–253

    Article  PubMed  Google Scholar 

  • Zhao X, Xu X, Zhang Q et al (2011) Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving »metronomic« zoledronic acid. BMC Cancer 11: 403

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Forschungsabteilung Charité – Universitätsmedizin Berlin, Schumannstr. 20/21, 10117, Berlin, Deutschland

    Klaus Jung

  2. Klinik für Urologie und Kinderurologie Sana Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach am Main, Deutschland

    Michael Lein

Authors
  1. Klaus Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Jung .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jung, K., Lein, M. (2014). Biomarker des Knochenstoffwechsels in Serum und Urin bei ossären Metastasen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation